Artikel
High expression of Cyclooxygenase-2, Prostaglandin E2 and the E-type Prostanoid receptors EP2 and EP4 in zygapophyseal joints of patients with Ankylosing Spondylitis
Meeting Abstract
Suche in Medline nach
Autoren
-
Janine Bleil
- Charité - Universitätsmedizin Berlin, Medizinische Klinik I, Rheumatologie, Berlin
-
Heiner Appel
- Charité - Universitätsmedizin Berlin, Rheumatologie, Berlin
-
René Maier
- Charité - Universitätsmedizin Berlin, Berlin
-
Joachim Sieper
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektologie, Rheumatologie, Berlin
-
Uta Syrbe
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektologie, Rheumatologie, Berlin
| Veröffentlicht: | 12. September 2014 |
|---|
Gliederung
Text
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for patients with ankylosing spondylitis (AS). Apart from their beneficial effect on signs and symptoms, NSAIDs seem to retard radiographic progression. To unravel the role of PGE2 in local inflammation and joint remodeling in AS, we analyzed the expression of COX-2, PGE2, and of that PGE2 receptors, EP2 and EP4, in joints of AS patients undergoing joint ankylosis.
Methods: Expression of COX-2, PGE2, EP2 and EP4 was determined in zygapophyseal joints from 19 AS, 11 osteoarthritis (OA) patients and 12 autopsy controls (CO) within the subchondral bone marrow, in osteocytes, chondrocytes and in fibrous tissue cells.
Results: see Table 1 [Tab. 1]
Conclusion:
- 1.
- Elevated expression of PGE2 including COX-2 within the subchondral bone marrow suggests local activation of this pathway.
- 2.
- PGE2 may directly control the activity of chondrocytes and fibrous tissue cells in AS joints as these cells showed high expression of EP2 and EP4 receptors.
